Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

Inclusion Criteria: * Newly diagnosed unilateral retinoblastoma * Underwent enucleation as primary therapy within the past 5 weeks * Must enroll and submit pathology slides within 21 days of enucleation * Adjuvant chemotherapy must begin within 35 days after enucleation * Disease with or without high-risk histopathologic features * High-risk features are defined as any of the following: * Posterior uveal invasion (includes choroidal invasion) * Any degree of concomitant choroid and/or optic nerve involvement * Tumor involving the optic nerve posterior to the lamina cribrosa as an independent finding * Scleral invasion * Anterior chamber seeding * Ciliary body infiltration * Iris infiltration * No evidence of extraocular retinoblastoma clinically, by CT scan, or by MRI of the brain and orbits with and without gadolinium * No tumor at the cut end of the optic nerve on any eye enucleated as evidenced by histologic examination prior to study entry * No systemic metastases as evidenced by bone marrow scan, bone scan, or any other additional test at study entry * Lansky performance status 50-100% * Hemoglobin \> 8 g/dL * Absolute neutrophil count ≥ 1,000/mm³ * Platelet count ≥ 100,000/mm³ * Creatinine adjusted according to age as follows: * No greater than 0.4 mg/dL (≤ 5 months) * No greater than 0.5 mg/dL (6 months -11 months) * No greater than 0.6 mg/dL (1 year-23 months) * No greater than 0.8 mg/dL (2 years-5 years) * No greater t…